Premium
Adjuvant chemotherapy decreases and postpones distant metastasis in extremity stage IIB/III synovial sarcoma patients
Author(s) -
Chen Yong,
Yang Yun,
Wang Chunmeng,
Shi Yingqiang
Publication year - 2012
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23061
Subject(s) - medicine , synovial sarcoma , docetaxel , regimen , chemotherapy , stage (stratigraphy) , gemcitabine , oncology , metastasis , sarcoma , adjuvant , adjuvant therapy , gastroenterology , surgery , pathology , cancer , paleontology , biology
Abstract Background and Objectives The role of adjuvant chemotherapy (AC) in treatment of synovial sarcoma remains controversial. Aim of our study is to investigate the influence of AC on disease‐specific survival and metastasis free survival, the difference in time to metastasis (TTM) was also analyzed. Materials and Methods Seventy‐six cases of stage IIB/III synovial sarcoma from January 1993 to December 2008 were retrospectively analyzed. All the 76 patients were treated with surgical resection. AC regimen included first line MAID or AIM, second line Gemcitabine + Docetaxel with sufficient dose intensity. The clinical, pathologic, and treatment variables were analyzed for disease specific survival (DSS), metastasis free survival (MFS) and TTM. Results Median follow up period was 68 months. 51 patients received AC (51/76, 67%), 25 received no adjuvant chemotherapy (NAC, 25/76, 33%). The 5‐year DSS of the AC patients was 73%(58–87%) compared with 31%(19–52%) for the NAC patients ( P = 0.001). AC was also independently associated with improved MFS ( P = 0.008) and prolonged TTM ( P = 0.001). Conclusions Patients with stage IIB/III synovial sarcoma might benefit in DSS, MFS, and a prolonged TTM from AC. J. Surg. Oncol. 2012; 106:162–168. © 2012 Wiley Periodicals, Inc.